Market Overview:
The global inflammatory skin diseases drugs market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of inflammatory skin diseases, rising awareness about these diseases, and technological advancements in the field of dermatology. The global inflammatory skin diseases drugs market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into retinoids, corticosteroids, calcineurin inhibitors (CNIs), and others. CNIs are expected to witness high growth during the forecast period owing to their high efficacy in treating various types of inflammatory skin diseases such as psoriasis and eczema. On the basis of application, hospital pharmacies accounted for a major share of this market in 2017; however, retail pharmacies are expected to witness higher growth during the forecast period owing to their growing popularity among consumers across different regions worldwide.
Product Definition:
Inflammatory skin diseases drugs are used to treat conditions that cause the skin to become inflamed. This type of medication includes creams, ointments, and pills. They are important because they can help reduce inflammation and improve the appearance of the skin.
Retinoids:
Retinoids is a group of vitamin-like substances, which act as retinol's precursor and are found in animal and plant foods. Vitamin A has two forms - retinol and carotenoids. Retinols can be converted to carotenoids by the body, but this process is not efficient enough to meet the body's needs for vitamin A. Hence, supplements or food containing high levels of these vitamins are recommended for optimum health.
Corticosteroids:
Corticosteroids are the group of drugs whose main function is to reduce inflammation by suppressing the immune response. Corticosteroid creams, ointments, lotions or tablets can be used for treating a variety of inflammatory skin diseases such as atopic dermatitis (AD), psoriasis (Ps), contact dermatitis (CD) and septicemia. The most commonly used topical corticosteroid in the U.
Application Insights:
The acute skin reactions segment dominated the global inflammatory skin diseases drugs market in 2017. Acute skin reactions include contact dermatitis and eczema. Contact dermatitis is a reaction of the epidermis to external agents that causes erythema, edema, and crusting at the site of exposure. It is most commonly seen in patients who have previously had eczemas or allergic rhinitis (hayfever).
Eczema is a chronic relapsing disease characterized by excoriations, vesicles, papules and pustules on the scalp as well as face & neck regions in adults & children alike.
Regional Analysis:
North America dominated the global inflammatory skin diseases drugs market in 2017. The presence of key players, favorable reimbursement policies, and increasing prevalence of psoriasis are some factors responsible for its large share. According to Psoriasis Foundation International (PFI), around 2 million people suffer from psoriasis in the U.S., which is about 6% of the population aged 18 years and above.
Asia Pacific region is anticipated to witness lucrative growth over the forecast period owing to rising disposable income levels coupled with growing awareness regarding treatment options for IBDs such as Crohn’s disease or ulcerative colitis among patients suffering from inflammatory bowel disease (IBD).
Growth Factors:
- Increasing incidence of inflammatory skin diseases such as psoriasis, atopic dermatitis, and acne vulgaris is expected to drive the demand for inflammatory skin diseases drugs market over the forecast period.
- Rising awareness about available treatment options for various types of inflammatory skin diseases is anticipated to fuel the growth of this market in the near future.
- Growing number of research and development activities focused on developing novel therapeutics for treating various forms of inflammatory skin diseases is projected to boost the growth prospects of this market in coming years.
- increasing prevalence of lifestyle-associated disorders such as obesity and diabetes mellitus that are known to cause or aggravate inflammation is likely to create lucrative opportunities for players operating in this market during the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Inflammatory Skin Diseases Drugs Market Research Report
By Type
Retinoids, Corticosteroids, Calcineurin Inhibitors, Others
By Application
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Companies
Pfizer, Merck, AbbVie, Novartis, Boehringer Ingelheim, Amgen, Eli Lilly
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
236
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global Inflammatory Skin Diseases Drugs Market Report Segments:
The global Inflammatory Skin Diseases Drugs market is segmented on the basis of:
Types
Retinoids, Corticosteroids, Calcineurin Inhibitors, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Merck
- AbbVie
- Novartis
- Boehringer Ingelheim
- Amgen
- Eli Lilly
Highlights of The Inflammatory Skin Diseases Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Retinoids
- Corticosteroids
- Calcineurin Inhibitors
- Others
- By Application:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Inflammatory Skin Diseases Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Inflammatory skin diseases drugs are medications used to treat conditions that cause inflammation, such as psoriasis, dermatitis, and eczema. These drugs can help reduce the symptoms of these conditions and may also help prevent them from recurring.
Some of the major companies in the inflammatory skin diseases drugs market are Pfizer, Merck, AbbVie, Novartis, Boehringer Ingelheim, Amgen, Eli Lilly.
The inflammatory skin diseases drugs market is expected to register a CAGR of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Inflammatory Skin Diseases Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Inflammatory Skin Diseases Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Inflammatory Skin Diseases Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Inflammatory Skin Diseases Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Inflammatory Skin Diseases Drugs Market Size & Forecast, 2018-2028
4.5.1 Inflammatory Skin Diseases Drugs Market Size and Y-o-Y Growth
4.5.2 Inflammatory Skin Diseases Drugs Market Absolute $ Opportunity
Chapter 5 Global Inflammatory Skin Diseases Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Inflammatory Skin Diseases Drugs Market Size Forecast by Type
5.2.1 Retinoids
5.2.2 Corticosteroids
5.2.3 Calcineurin Inhibitors
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Inflammatory Skin Diseases Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Inflammatory Skin Diseases Drugs Market Size Forecast by Applications
6.2.1 Hospital Pharmacies
6.2.2 Retail Pharmacies
6.2.3 Online Pharmacies
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Inflammatory Skin Diseases Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Inflammatory Skin Diseases Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Inflammatory Skin Diseases Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Inflammatory Skin Diseases Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Inflammatory Skin Diseases Drugs Market Size Forecast by Type
9.6.1 Retinoids
9.6.2 Corticosteroids
9.6.3 Calcineurin Inhibitors
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Inflammatory Skin Diseases Drugs Market Size Forecast by Applications
9.10.1 Hospital Pharmacies
9.10.2 Retail Pharmacies
9.10.3 Online Pharmacies
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Inflammatory Skin Diseases Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Inflammatory Skin Diseases Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Inflammatory Skin Diseases Drugs Market Size Forecast by Type
10.6.1 Retinoids
10.6.2 Corticosteroids
10.6.3 Calcineurin Inhibitors
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Inflammatory Skin Diseases Drugs Market Size Forecast by Applications
10.10.1 Hospital Pharmacies
10.10.2 Retail Pharmacies
10.10.3 Online Pharmacies
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Inflammatory Skin Diseases Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Inflammatory Skin Diseases Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Inflammatory Skin Diseases Drugs Market Size Forecast by Type
11.6.1 Retinoids
11.6.2 Corticosteroids
11.6.3 Calcineurin Inhibitors
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Inflammatory Skin Diseases Drugs Market Size Forecast by Applications
11.10.1 Hospital Pharmacies
11.10.2 Retail Pharmacies
11.10.3 Online Pharmacies
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Inflammatory Skin Diseases Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Inflammatory Skin Diseases Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Inflammatory Skin Diseases Drugs Market Size Forecast by Type
12.6.1 Retinoids
12.6.2 Corticosteroids
12.6.3 Calcineurin Inhibitors
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Inflammatory Skin Diseases Drugs Market Size Forecast by Applications
12.10.1 Hospital Pharmacies
12.10.2 Retail Pharmacies
12.10.3 Online Pharmacies
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Inflammatory Skin Diseases Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Inflammatory Skin Diseases Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Inflammatory Skin Diseases Drugs Market Size Forecast by Type
13.6.1 Retinoids
13.6.2 Corticosteroids
13.6.3 Calcineurin Inhibitors
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Inflammatory Skin Diseases Drugs Market Size Forecast by Applications
13.10.1 Hospital Pharmacies
13.10.2 Retail Pharmacies
13.10.3 Online Pharmacies
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Inflammatory Skin Diseases Drugs Market: Competitive Dashboard
14.2 Global Inflammatory Skin Diseases Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Merck
14.3.3 AbbVie
14.3.4 Novartis
14.3.5 Boehringer Ingelheim
14.3.6 Amgen
14.3.7 Eli Lilly
